PLANTAMED

PlantaMed is a biotechnology company based in Luxembourg that specializes in the development of botanical-derived pharmaceuticals, with a primary focus on extracts from the Artemisia annua plant. The company leverages advanced extraction and standardization technologies to create pharmaceutical-grade treatments for inflammatory and infectious diseases. Its lead candidate, PM-001 (also known in clinical contexts as CimetrA), has been evaluated in Phase 2 clinical trials for its ability to modulate the cytokine storm in patients with COVID-19. PlantaMed's research is deeply rooted in collaborations with the Max Planck Institute for Colloids and Interfaces, focusing on the therapeutic potential of artemisinin and other plant terpenes. The company aims to bridge the gap between traditional herbal medicine and modern evidence-based drug development. Beyond respiratory infections, PlantaMed is exploring applications for its plant-based platform in malaria and oncology.